MX2015003800A - Terapia de combinacion mediante el uso de belinostat y trabetedina. - Google Patents

Terapia de combinacion mediante el uso de belinostat y trabetedina.

Info

Publication number
MX2015003800A
MX2015003800A MX2015003800A MX2015003800A MX2015003800A MX 2015003800 A MX2015003800 A MX 2015003800A MX 2015003800 A MX2015003800 A MX 2015003800A MX 2015003800 A MX2015003800 A MX 2015003800A MX 2015003800 A MX2015003800 A MX 2015003800A
Authority
MX
Mexico
Prior art keywords
belinostat
trabectedin
combination therapy
solvate
hydrate
Prior art date
Application number
MX2015003800A
Other languages
English (en)
Inventor
Kamille Dumong Erichsen
Original Assignee
Onxeo Dk Branch Of Onxeo S A France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo Dk Branch Of Onxeo S A France filed Critical Onxeo Dk Branch Of Onxeo S A France
Publication of MX2015003800A publication Critical patent/MX2015003800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere generalmente a terapias para el tratamiento de enfermedades y trastornos que son mediados por histona desacetilasa (HDAC) (por ejemplo, cáncer, incluidos, por ejemplo, cáncer de ovario, sarcoma de tejidos blandos, osteosarcoma, etc.) que utilizan una combinación (v.gr., una combinación sinérgica) de (a) belinostat, o una sal, hidrato o solvato del mismo y (b) trabectedina, o una sal, hidrato o solvato de la misma.
MX2015003800A 2012-09-28 2013-09-26 Terapia de combinacion mediante el uso de belinostat y trabetedina. MX2015003800A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707063P 2012-09-28 2012-09-28
GBGB1217439.7A GB201217439D0 (en) 2012-09-28 2012-09-28 Combination therapy
PCT/IB2013/058891 WO2014049549A1 (en) 2012-09-28 2013-09-26 Combination therapy using belinostat and trabectedin

Publications (1)

Publication Number Publication Date
MX2015003800A true MX2015003800A (es) 2015-10-05

Family

ID=47225413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003800A MX2015003800A (es) 2012-09-28 2013-09-26 Terapia de combinacion mediante el uso de belinostat y trabetedina.

Country Status (10)

Country Link
US (1) US20150231134A1 (es)
EP (1) EP2900271A1 (es)
JP (1) JP2015531367A (es)
KR (1) KR20150063070A (es)
BR (1) BR112015006738A2 (es)
CA (1) CA2884923A1 (es)
GB (1) GB201217439D0 (es)
MX (1) MX2015003800A (es)
RU (1) RU2015109086A (es)
WO (1) WO2014049549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
RU2747228C2 (ru) 2015-04-29 2021-04-29 Радиус Фармасьютикалз, Инк. Способы лечения рака
WO2017133544A1 (zh) * 2016-02-04 2017-08-10 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
MX2019003311A (es) * 2016-09-27 2019-07-08 Radius Health Inc Metodos para tratamiento de cancer de ovario.
PL3565542T3 (pl) 2017-01-05 2024-07-29 Radius Pharmaceuticals, Inc. Postacie polimorficzne rad1901-2hcl
US11266614B2 (en) * 2017-06-30 2022-03-08 Onxeo Oral formulations of belinostat
EA039150B1 (ru) * 2017-07-03 2021-12-10 Онксео Новые пероральные составы на основе белиностата
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
AU2021256746A1 (en) * 2020-04-15 2022-11-03 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
JP5156392B2 (ja) * 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤を用いる併用療法
WO2007054719A2 (en) * 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent

Also Published As

Publication number Publication date
KR20150063070A (ko) 2015-06-08
JP2015531367A (ja) 2015-11-02
WO2014049549A1 (en) 2014-04-03
RU2015109086A (ru) 2016-11-20
CA2884923A1 (en) 2014-04-03
GB201217439D0 (en) 2012-11-14
US20150231134A1 (en) 2015-08-20
BR112015006738A2 (pt) 2017-07-04
EP2900271A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
MX2015003800A (es) Terapia de combinacion mediante el uso de belinostat y trabetedina.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA033163B1 (ru) Ингибиторы глутаминазы
MX351943B (es) Compuestos inhibidores de metaloenzima.
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
IN2014DN00286A (es)
IN2014MN00093A (es)
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
IN2014DN06792A (es)
IN2014MN01378A (es)
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
EA201692216A1 (ru) Пирролидиновые модуляторы gpr40 для лечения заболеваний, таких как диабет
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
IN2013MU03118A (es)
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PT3724173T (pt) Compostos para o tratamento de distúrbios neuromusculares